Sign In
Buy LLY
$1,131.42
+6.15 (+0.547%)
At Close: Jun 05, 2026
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
01:11pm, Wednesday, 28'th Aug 2024
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
06:32am, Wednesday, 28'th Aug 2024
Eli Lilly is exploring whether its newest hit drug could be used to treat psoriasis. AbbVie's newest hit drugs already treat psoriasis, among other conditions.
Why Eli Lilly is a top GLP-1 stock: Roundhill CEO
07:42pm, Tuesday, 27'th Aug 2024
Pharmaceutical companies have significantly grown over the last year as demand for GLP-1 weight-loss drugs continues to skyrocket. Roundhill Investments CEO Dave Mazza joins Market Domination for the
Lilly Sells Zepbound Vials at Lower Cost
03:59pm, Tuesday, 27'th Aug 2024
Lilly sells self-inject vials of popular weight-loss drug Zepbound at a 50% discount -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't
3-Stock Lunch: Nvidia, Eli Lilly, Paramount
03:17pm, Tuesday, 27'th Aug 2024
David Bahnsen, The Bahnsen Group CIO, joins 'Power Lunch' to discuss stock play for three stocks.
Hims & Hers Health Stock Takes Hit as Eli Lilly Offers Cheaper Weight-Loss Drug
12:21pm, Tuesday, 27'th Aug 2024
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund's 2024 Corporate Membership Program at ‘Champion' Level
11:01am, Tuesday, 27'th Aug 2024
ROCKVILLE, Md., Aug. 27, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2024 class in AKF's Corporate Membe
Eli Lilly Launches Cheaper Single-Use Vials of Weight-Loss Drug Zepbound
10:16am, Tuesday, 27'th Aug 2024
Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the company's popular weight-loss drugs.
Eli Lilly just halved the price of its weight-loss drug — declaring war on the booming market of knock-offs
10:11am, Tuesday, 27'th Aug 2024
Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit weight-loss drugs. Zepbound will be sold for $399-$549 per month, compared to a previous list price of $1,059
Eli Lilly cuts cost of certain Zepbound doses by at least 50%
10:02am, Tuesday, 27'th Aug 2024
Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than "all other incretin GLP-1 medicines for obesity.
Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.
10:00am, Tuesday, 27'th Aug 2024
Its tirzepatide reduces the chance of developing diabetes, according to a new study. The population of people who might develop diabetes in the future is very large.
Eli Lilly's Zepbound single-dose vials will expand access to more patients: Mizuho's Jared Holz
09:30am, Tuesday, 27'th Aug 2024
Jared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss Eli Lilly's announcement to release single-dose vials of its anti-obesity drug Zepbound, how the news will exp
The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace
09:13am, Tuesday, 27'th Aug 2024
Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.
Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.
08:44am, Tuesday, 27'th Aug 2024
The new option is priced at a 50% or more discount compared to other weight-loss drugs.
Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
07:38am, Tuesday, 27'th Aug 2024
CNBC's Joe Kernen reports on the latest news.
